Point72 Asia Singapore Pte. Ltd. Invests $52,000 in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 31,831 shares of the company’s stock, valued at approximately $52,000.

Several other institutional investors and hedge funds have also bought and sold shares of CRBU. Point72 DIFC Ltd grew its holdings in shares of Caribou Biosciences by 389.4% in the second quarter. Point72 DIFC Ltd now owns 30,157 shares of the company’s stock worth $49,000 after purchasing an additional 23,995 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Caribou Biosciences by 66.5% in the first quarter. China Universal Asset Management Co. Ltd. now owns 17,024 shares of the company’s stock valued at $88,000 after acquiring an additional 6,798 shares during the period. Entropy Technologies LP bought a new position in shares of Caribou Biosciences during the first quarter valued at about $113,000. Hsbc Holdings PLC boosted its holdings in shares of Caribou Biosciences by 476.4% during the second quarter. Hsbc Holdings PLC now owns 80,867 shares of the company’s stock worth $129,000 after purchasing an additional 66,838 shares during the period. Finally, Bayesian Capital Management LP bought a new stake in shares of Caribou Biosciences in the first quarter worth about $151,000. 77.51% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have commented on CRBU. Royal Bank of Canada reaffirmed an “outperform” rating and set a $14.00 price target on shares of Caribou Biosciences in a research report on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Caribou Biosciences in a research note on Tuesday, September 3rd. Finally, Evercore ISI downgraded shares of Caribou Biosciences from an “outperform” rating to an “inline” rating and reduced their price objective for the company from $13.00 to $3.00 in a research report on Monday, June 3rd. One research analyst has rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.25.

Caribou Biosciences Stock Down 1.0 %

CRBU opened at $1.96 on Tuesday. Caribou Biosciences, Inc. has a 52 week low of $1.50 and a 52 week high of $8.33. The business has a 50 day moving average of $2.07 and a 200-day moving average of $2.81. The stock has a market cap of $177.02 million, a PE ratio of -1.35 and a beta of 2.29.

Caribou Biosciences (NASDAQ:CRBU) last issued its earnings results on Tuesday, August 6th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.04. Caribou Biosciences had a negative net margin of 372.78% and a negative return on equity of 34.76%. The firm had revenue of $3.46 million for the quarter, compared to the consensus estimate of $3.31 million. Equities analysts anticipate that Caribou Biosciences, Inc. will post -1.76 EPS for the current year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.